RCKTW
ROCKET PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 28 ▲ Rocket Pharmaceuticals announced the sale of its Rare Pediatric Dise…
- May 7 Rocket Pharmaceuticals reported Q1 2026 net loss of -$47.6M (-$0.42/…
- Jun 15 ▲ Short interest falls 66.2% to 16.5K
- Jun 30 ▲ Short interest falls 77.6% to 3.7K
- Jul 10 Reg SHO: Reg SHO Threshold: RCKTW entered the threshold list
- Jul 15 ▼ Short interest jumps 3848.2% to 146.4K
- Jul 23 Reg SHO: Reg SHO Threshold: RCKTW entered the threshold list
- Jul 24 Reg SHO: Reg SHO Threshold: RCKTW exited the threshold list
- Jul 31 ▲ Short interest falls 66.5% to 49.1K
- Sep 2 Trading halt: Trading Halt: RCKTW, T12 (Additional Information Requested)
- Sep 2 Trading halt: Trading Halt: RCKTW, D (Security Deletion)
- Sep 3 Trading halt: Halt Resumed: RCKTW, trading resumed after D (Security Del…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q4 2025: 0 added (0 new), 1 trimmed or exited.
- Short sellersSTEADY
Short interest +11.8% to 55.4K shares. 1.0 days to cover, ≈0.1% of shares.
- TrendRANGE
19% below its 50-day average. New closing low $2.16 on Nov 16.
Who's buying
13F· Q4 2025| Fund | Move | Value |
|---|---|---|
| Walleye Capital LLC | TRIM | $6.9K |
| Walleye Trading LLC | DOUBLED | $2.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $16.5M |
| Next Q | None | None | No data | $624.6K |
| Current FY | None | None | No data | $1.1M |
| Next FY | None | None | No data | $11.2M |
Washington
Short side
FINRA· Aug 31, 2026| Sep 2, 2026 | Deletion | Resumed |
SecBot reports
4 filings · 1 bullish · 0 bearish · 1 mixed · 2 neutral- NEUTRAL 144May 13, 2026
Gaurav Shah, an officer and director of Rocket Pharmaceuticals, filed a Form 144 notice of intent…
This is a routine tax-withholding sale by an insider following equity vesting. The dollar amount is negligible relative to market cap. No trading action warranted; monitor for any larger insider…
- MIXED 8-KMay 7, 2026
Rocket Pharmaceuticals reported Q1 2026 net loss of -$47.6M (-$0.42/share), improving from -$61.3M…
The KRESLADI approval and PRV monetization remove near-term financing risk and de-risk the pipeline; watch for Danon disease program update in H2 2026 as next major catalyst. Market cap of $1M for…
- NEUTRAL 144May 7, 2026
Officer Sarbani Chaudhuri intends to sell 17,650 shares of RCKTW common stock (approx. $67,740) to…
The sale is tax-motivated and expected; watch for any subsequent Form 4 filings to confirm execution. Given RCKTW's micro-cap status and low liquidity, even a small sale could pressure the stock.
- BULLISH 8-KApr 28, 2026
Rocket Pharmaceuticals announced the sale of its Rare Pediatric Disease Priority Review Voucher…
The $180M sale is a significant positive catalyst for RCKTW given the tiny market cap (~$1M). Monitor HSR clearance and closing. If completed, expect a sharp re-rating as cash balances will vastly…
All RCKTW filing & press-release reports (4)
- 144 reportMay 13, 2026
- 8-K reportMay 7, 2026
- 144 reportMay 7, 2026
- 8-K reportApr 28, 2026